Cargando…
A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects
INTRODUCTION: Iberdomide, a novel cereblon modulator (CELMoD(®)), is currently under clinical investigation for hematology indications. To evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of iberdomide and its major active metabolite M12, a phase 1, multicenter, open-label s...
Autores principales: | Cheng, Yiming, Ye, Ying, Gaudy, Allison, Ghosh, Atalanta, Xue, Yongjun, Wang, Alice, Zhou, Simon, Li, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985425/ https://www.ncbi.nlm.nih.gov/pubmed/36880014 http://dx.doi.org/10.2147/CPAA.S397826 |
Ejemplares similares
-
First‐in‐Human, Single‐ and Multiple‐Ascending‐Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator
por: Ye, Ying, et al.
Publicado: (2020) -
Pharmacokinetics of Dalfampridine Extended Release 7.5-mg Tablets in Healthy Subjects and Individuals With Mild and Moderate Renal Impairment: An Open-Label Study
por: Samara, Emil, et al.
Publicado: (2014) -
Biological impact of iberdomide in patients with active systemic lupus erythematosus
por: Lipsky, Peter E, et al.
Publicado: (2022) -
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
por: Schnell, David, et al.
Publicado: (2014) -
Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects
por: Tran, Jonathan Q., et al.
Publicado: (2020)